New GlaxoSmithKline lung drug nabs thumbs-up from FDA experts

An FDA advisory panel gave an approval stamp to GlaxoSmithKline's ($GSK) new lung drug, Breo. The agency advisers weren't unanimous in backing GSK's follow-up to now-off-patent Advair, however; some expressed reservations about Breo's ability to reduce exacerbations in COPD patients and about its safety. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.